SCHEMBL13600560

SCHEMBL13600560

NC[C@@H]1CCN(CCOCCO)C[C@H]1O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GBA1 P04062 6/20 0.39
HTR1A P08908 1/20 0.34
CYP2D6 P10635 2/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
CYP2C19 P33261 1/20 0.33
TSHR P16473 1/20 0.31
MAPK1 P28482 1/20 0.31
ABCB11 O95342 1/20 0.31
CHRM2 P08172 1/20 0.31
ADRA2A P08913 1/20 0.31
DRD2 P14416 1/20 0.31
ADRA2B P18089 1/20 0.31
ADRA2C P18825 1/20 0.31
DRD4 P21917 1/20 0.31
HRH2 P25021 1/20 0.31
HTR2A P28223 1/20 0.31
HTR7 P34969 1/20 0.31
ADRA1A P35348 1/20 0.31
HRH1 P35367 1/20 0.31
DRD3 P35462 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13607593 1.00 GBA1 (0.39) GBA1HTR1ACYP2D6SMN1; SMN2CYP2C19
SCHEMBL13610706 0.85 GBA1 (0.39) GBA1HRH2HRH1MEN1KMT2A
SCHEMBL13600556 0.85 GBA1 (0.39) GBA1HRH2HRH1MEN1KMT2A
SCHEMBL14610195 0.85 GBA1 (0.39) GBA1HRH2HRH1MEN1KMT2A
SCHEMBL13607569 0.85 GBA1 (0.39) GBA1HRH2HRH1MEN1KMT2A
SCHEMBL13607539 0.78 GBA1 (0.42) GBA1HTR1AADRA2CHRH2ADRA1A
SCHEMBL13600568 0.78 GBA1 (0.42) GBA1HTR1AADRA2CHRH2ADRA1A
SCHEMBL3713854 0.78 GBA1 (0.42) GBA1HTR1AADRA2CHRH2ADRA1A
SCHEMBL4473375 0.78 GLB1 (0.53) GBA1HTR1ADRD2DRD4DRD3
SCHEMBL13607587 0.78 GLB1 (0.53) GBA1HTR1ADRD2DRD4DRD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7635706-B2 1-butyl-3-hydroxy4-piperidinyl)methyl 8-amino-7-chloro-2,3-dihydro-1,4-benzodioxin-5-carboxylate and chemical intermediates; treating hypermotility, irritable bowel syndrome (IBS) constipation or diarrhea predominant IBS, pain and non-pain predominant IBS and bowel hypersensitivity JANSSEN PHARMACEUTICA NV (BE) 2009-12-22 US disclosed
US-20070032486-A1 5Ht4-antagonistic 4-(aminomethyl)-piperidine benzamides JANSSEN PHARMACEUTICA NV (BE) 2007-02-08 US disclosed
US-20070032486-A1 5Ht4-antagonistic 4-(aminomethyl)-piperidine benzamides JANSSEN PHARMACEUTICA NV (BE) 2007-02-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070032486-A1 5Ht4-antagonistic 4-(aminomethyl)-piperidine benzamides HTR4, HTR2B, TPH2 GBA1 2108/4885HTR1A 10/4885CYP2D6 529/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.